Introducing
QX600™ Droplet Digital™ PCR (ddPCR™) System
The Circulating Tumor DNA (ctDNA) Sample Analysis Solution.
Unmatched Sensitivity.
Industry Leading Accuracy and Precision.
Maximize Clinical Research Impact
Unrivaled performance for detecting low-abundance targets
Highly versatile Platform
Quantify SNPs, structural variants, methylation, perform RNA expression analysis, and more
Conserve Precious Samples
Advanced six-color multiplexing
Simplify Lab Logistics
Low burden workflow, same-day results
Advanced
Six-Color
Multiplexing
The six-color QX600 system produces unmatched precision and sensitivity enabling clear discrimination and absolute quantification of up to 12 biomarkers per well
- Industry leading performance demonstrated with traceable material from the National Measurement Institute (NMI, Australia)
Low-Burden
Workflow
User-Friendly
Software
Results that are easy to analyze:
- Highly intuitive dashboard display
- Rapid PC-based analysis of up to 96 samples per run
- Easily create, modify, and deploy analysis protocols
Track Record
of Success
Broad global adoption of ddPCR technology has established it as the market leader in clinical research:
- Robust platform utilized in over 6,300 publications, hundreds of which investigate ctDNA analysis and other oncology applications
- Extensive catalog of highly optimized assays, many developed with external users and experts
QX600 Applications
As an enabling technology, Droplet Digital PCR has helped drive numerous research and clinical studies. This includes broad global adoption in clinical labs for liquid biopsy monitoring or solid tumors, hematology oncology, and cancer research. Use in biopharma for cell and gene therapy, discovery, and manufacturing quality control has helped solidify ddPCR as a market leading technology.
Recent studies have leveraged ddPCR for disease testing in Oncology. Solid tumor monitoring and hematology oncology in particular are applications in which ddPCR may be particularly advantageous.
The sensitivity, accuracy, and throughput of ddPCR is highly valuable for circulating tumor DNA (ctDNA) analysis. Further, ddPCR is well suited for clinical research focusing on minimal residual disease (MRD) monitoring and tumor responsiveness to therapy. ddPCR compliments NGS technology and even surpasses it for specific use cases, and the logistic and economic advantages of ddPCR may make it an ideal platform for cancer diagnostics and treatment labs.
